Page last updated: 2024-09-04

ml-3000 and Heart Disease, Ischemic

ml-3000 has been researched along with Heart Disease, Ischemic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S	1

Other Studies

1 other study(ies) available for ml-3000 and Heart Disease, Ischemic

Article	Year
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3 Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors	2006

Article

Year

The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.

European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3

Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors

2006